3-D Printing Technology Enhances Limb Preservation in Cancer Operations
Limb preservation is now the procedure of choice for the treatment of patients with bone cancer.
Related Articles
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer
Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.
ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC
Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma
Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.
Luspatercept Increases Likelihood of Lasting Transfusion Independence in ESA-Naive, Lower-Risk MDS
Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.
Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL
Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions
Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.
Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC
Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.
T-DXd Rechallenge Is Safe After Grade 1 ILD in Breast Cancer and Other Solid Tumors
A high rate of patients with breast cancer and other solid tumors were rechallenged with trastuzumab deruxtecan after grade 1 interstitial lung disease.